Allogene Therapeutics (ALLO) Change in Acquisitions & Divestments (2019 - 2025)
Allogene Therapeutics (ALLO) has disclosed Change in Acquisitions & Divestments for 7 consecutive years, with $234.2 million as the latest value for Q4 2025.
- Quarterly Change in Acquisitions & Divestments fell 45.16% to $234.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $234.2 million through Dec 2025, down 45.84% year-over-year, with the annual reading at $234.2 million for FY2025, 45.84% down from the prior year.
- Change in Acquisitions & Divestments hit $234.2 million in Q4 2025 for Allogene Therapeutics, up from -$110.3 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $427.1 million in Q4 2024 to a low of -$290.7 million in Q3 2023.
- Historically, Change in Acquisitions & Divestments has averaged $77.8 million across 5 years, with a median of $110.2 million in 2024.
- Biggest five-year swings in Change in Acquisitions & Divestments: skyrocketed 123.06% in 2021 and later plummeted 489.75% in 2023.
- Year by year, Change in Acquisitions & Divestments stood at $82.5 million in 2021, then crashed by 415.46% to -$260.4 million in 2022, then fell by 11.64% to -$290.7 million in 2023, then soared by 246.91% to $427.1 million in 2024, then tumbled by 45.16% to $234.2 million in 2025.
- Business Quant data shows Change in Acquisitions & Divestments for ALLO at $234.2 million in Q4 2025, -$110.3 million in Q3 2025, and $53.8 million in Q2 2025.